InMed Pharmaceuticals (INM) Total Liabilities (2019 - 2026)

InMed Pharmaceuticals has reported Total Liabilities for 8 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 0.72% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 0.72% YoY), and the FY2025 full-year result was $2.1 million, down 18.0% from the prior year.
• Total Liabilities for Q1 2026 stood at $2.2 million, up from $1.6 million in the prior quarter.
• The five-year high for Total Liabilities was $4.6 million in Q1 2022, with the low at $1.3 million in Q3 2023.
• Historically, Total Liabilities has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 138.23% — and 2023, when it sank 62.55%.
• InMed Pharmaceuticals' Total Liabilities stood at $2.6 million in 2022, then slipped by 3.92% to $2.5 million in 2023, then slipped by 6.57% to $2.3 million in 2024, then tumbled by 30.88% to $1.6 million in 2025, then surged by 39.79% to $2.2 million in 2026.
• The last three Total Liabilities figures came in at $2.2 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.